Corcept Therapeutics Announces Preliminary Results of Tender Offer
MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (Nasdaq: CORT), a commercial-stage company engaged in the...
Cancer
TransCode Therapeutics Announces Agreement with Triton Funds for Sale of Series A Convertible Preferred Stock
BOSTON, April 03, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to...
Eloxx Pharmaceuticals Reports Fourth Quarter 2022 Financial and Operating Results and Provides Business Update
Three patients now dosed in Phase 2 clinical study evaluating ELX-02 for the treatment of Alport syndrome; encouraging initial reduction...
Vaccinex Reports 2022 Financial Results and Provides Corporate Update of Continued Progress in Neurology and Oncology Clinical Programs
Expect to complete patient enrollment in the randomized Phase 1/2a SIGNAL-AD Alzheimer’s study in April 2023 with topline data anticipated...
AnPac Bio-Medical Science Announces Pricing of $3.0 Million Registered Direct Offering
New York, NY, March 31, 2023 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (the “Company”) (NASDAQ: ANPC), a company...
ABVC BioPharma Announces Fiscal Year 2022 Financial and Operational Results
FREMONT, CA, March 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (Nasdaq: ABVC), a biotechnology company specializing...
StageZero to Issue Q4 2022 Financial Results on Friday March 31
Toronto, Ontario--(Newsfile Corp. - March 30, 2023) - StageZero Life Sciences (TSX: SZLS) ("StageZero" or the "Company") today announced that...
StageZero to Issue Q4 2022 Financial Results and Hold Conference Call on Thursday March 30
Toronto, Ontario--(Newsfile Corp. - March 29, 2023) - StageZero Life Sciences (TSX: SZLS) ("StageZero" or the "Company") today announced that...
Nexcella Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy In The Context of U.S. Food And Drug Administration Approved BCMA CAR T Cells
LOS ANGELES, March 31, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”) today announced that an editorial...
Fennec Pharmaceuticals Receives Positive CHMP Opinion for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients
~ First Therapy Recommended for Approval in the European Union for Reducing the Risk of Cisplatin-induced Hearing Loss (Ototoxicity) in...
Checkpoint Therapeutics Announces $6.1 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
WALTHAM, Mass., March 31, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology...
Artelo Biosciences Reports Fiscal 2022 Year-End Financial Results and Provides Business Update
$17.5 Million in Cash and Marketable Securities as of December 31, 2022; Expected to Support Operations Into Second Half of...
Nexcella, an Immix Biopharma Subsidiary, Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy In The Context of U.S. Food And Drug Administration Approved BCMA CAR T Cells
LOS ANGELES, March 31, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”,...
TScan Therapeutics Announces CEO Transition
David Southwell steps down; Gavin MacBeath, Ph.D., Chief Scientific and Operating Officer, to serve as acting CEO Company reaffirms previously...
Immutep Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023
Media Release Efti plus pembrolizumab achieved mOS of 9.9 months and a 39% OS rate at 21 months, which compare...
Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Instil confirms cash runway beyond 2026 ITIL-306 phase 1 study anticipated to receive CTA clearance from UK MHRA in 2H'2023...
Bio-Path Holdings Reports Full Year 2022 Financial Results
Conference Call to be Held Today at 8:30 A.M. ETHOUSTON, March 31, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH),...
Junshi Biosciences Announces 2022 Full Year Financial Results and Provides Corporate Updates
SHANGHAI, China, March 31, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a...
Mendus AB: Change in number of shares and votes in Mendus AB (publ)
During March, the number of shares and votes in Mendus AB (publ) has changed as a result of 1,137,790 new...
Checkpoint Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
FDA accepted for filing the Biologics License Application for cosibelimab in patients with metastatic or locally advanced cutaneous squamous cell...